January 13, 2020 9:15am
38th Annual J.P. Morgan Healthcare Conference, 1/13 to 16/2020
Will the realities of drug pricing, affordability and reimbursement effect development platforms?
Pre-open indications: flashing a notice on 10 equities, you’d be aware if a subscriber
My version of the morning’s numbers is written to be informative; it’s includes what happened or will beyond the headline and shapes today’s markets as seen by RMi - SUBSCRIBE
Dow futures are UP +0.31% (+90points), S&P futures are UP +0.29% (+9 points) and NASDAQ futures are UP +0.42% (+38 points)
U.S. stock index futures are on the move upward on Monday to start off the week with a renewed optimism around U.S.-China trade relations;
European stocks flat as investors await trade and geopolitical developments with the pan-European Stoxx 600 slipping 0.1% by the afternoon;
Asia Pacific stocks mostly advanced as investors looking for prosperity from/to the inking of a trades/tariff deal, with MSCI’s broadest Asia-Pacific index excluding Japan gaining 0.49%.
The missing link in “calling the ball” in our universe or the cell and gene therapy sector is: taking an unholy imprecision of incomplete information
In these market environments, investors operate with incomplete information as a matter of course. How can a competitor take advantage of incomplete information? Read more about the use of RMi’s outlook here, stock by stock, day by day – they accumulate data for decision making!
The cell and gene therapy sector edged higher in 2019 even though it had many a bad session or sessions in a row and as a whole did not become that more valuable, just more expensive, as traders utilized this basket of stocks to manipulate or hope for a cure or cures.
Q4, year-end earnings are soon to be announced and are estimated to be up even less "progressive" than last year!
What a party-pooper, I hope to be proven wrong but, that’s my thoughts on the matter!
If you look at the quality of this non-growth, then the rose-tinted glasses of the average stock market investor quickly prove my contrarian view.
As stocks become more expensive, their benefit from earnings per-share growth diminishes.
Friday night’s post’s title: “as I wrote, the downside slide is starting.”
- The NASDAQ closed DOWN -24.57points (-0.27%);
- The IBB closed down -0.59% and XBI closed down -0.99%;
- The range of the 26 upside was +0.10% (EDIT) to +10.23% (RARE) while the 19 downside ranged from -0.02% (BOLD) to -15.43% (AGTC);
- 12 out of the 16 upside had higher than the 3 month average volume;
- 9 out of the 19 downside had higher than the 3 month average volume;
January registered 4 positive, 3 negative closes and 1 holiday, to date.
- December register 11 negative and 10 positive closes
- November registered 1 holiday, 12 positive and 8 negative close;
- October registered 10 positive, 1 neutral and 14 negative closes;
Companies in my headlights – It’s your decision; I provide an idea and context:
Pre-open indications: The spate of information or real "event' news being initiated at the JPMorgan healthcare conference will command attention ... if any
SELL – EDIT, RARE, RGNX and CLBS
BUY – ALYN, FATE, BLUE, AXGN CRSP and NTLA
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.